Management of Beta Blocker Toxicity

Introduction to Treatment

• The American Heart Association recommends glucagon as the first-line treatment for beta blocker overdose or severe toxicity, administered as a 50 μg/kg IV loading dose followed by a continuous infusion of 1-15 mg/hour titrated to patient response, with a mechanism that bypasses the beta-receptor site, directly activating adenylyl cyclase 1, 2
• For patients on long-term therapy with side effects, the American College of Cardiology suggests that if fluid retention occurs, increasing the diuretic dose rather than discontinuing the beta blocker is recommended, and if bradycardia with symptoms occurs, reducing the dose or temporarily discontinuing the beta blocker is advised 1
• The European Society of Cardiology recommends avoiding abrupt withdrawal of beta blockers, which can lead to rebound effects and clinical deterioration, and after stabilization, considering reintroduction at a lower dose with careful titration 3, 4, 5, 6

Pharmacological Interventions

• The American Heart Association suggests considering phosphodiesterase inhibitors (e.g., milrinone) for inotropic support in beta blocker toxicity 1, 2
• High-dose insulin euglycemic therapy may be considered, with an initial bolus of 1 unit/kg IV, infusion of 1-10 units/kg/hour, and maintenance of glucose levels between 100-250 mg/dL with dextrose infusion, while monitoring potassium levels closely 1
• Vasopressors/inotropes, such as epinephrine or norepinephrine infusion, may be used if hypotension persists, with dopamine as an alternative 1
• IV lipid emulsion therapy may be considered for lipophilic beta blockers (e.g., propranolol, metoprolol) 1

Special Considerations

• The American College of Cardiology recommends not relying solely on atropine for severe beta blocker toxicity, as its efficacy is inconsistent, and avoiding calcium channel blockers in beta blocker toxicity, as they may worsen bradycardia and hypotension 1, 2
• The European Society of Cardiology suggests monitoring glucose and potassium levels closely when using high-dose insulin therapy, and not abruptly discontinuing chronic beta blocker therapy in non-overdose situations, as this can lead to rebound tachycardia, hypertension, and myocardial ischemia 1, 3, 4, 5, 6
• Consider temporary pacing and review and discontinuation of other heart rate-slowing drugs (e.g., digoxin, amiodarone, diltiazem, verapamil) if HR <50 bpm with worsening symptoms 7

Treatment of Specific Beta Blocker Overdoses

• For water-soluble beta blockers (e.g., atenolol, sotalol), hemodialysis may be considered in massive overdose 1
• Discontinue metoprolol immediately if severe symptomatic bradycardia (HR <50 bpm with worsening symptoms) occurs, as recommended by the European Society of Cardiology 4
• Reintroduce beta-blockers at a low dose after resolution of severe bradycardia, using a "start low, go slow" approach with careful monitoring, as recommended by the European Society of Cardiology and the American College of Physicians 4, 5, 6

Patient Management and Education

• Participate in a supervised exercise program tailored to the patient's capabilities, starting with low-intensity activities and gradually increasing as tolerated, as recommended by the European Society of Cardiology 8
• Restrict sodium intake to ≤2g daily and consider fluid restriction to 2 liters daily if persistent fluid retention, as recommended by the American College of Cardiology 9
• Monitor daily weight, with instructions to contact the healthcare provider if weight increases by >1.5-2.0 kg over 2 days, as suggested by the European Society of Cardiology 4
• Schedule follow-up within 1 week after medication changes, monitoring vital signs, symptoms, and fluid status, and checking electrolytes and renal function, as recommended by the European Society of Cardiology 8
• Refer to a heart failure specialist/team, considering home health services for monitoring and education, and engaging social support, as recommended by the European Society of Cardiology 8
• Educate patients on recognizing worsening symptoms requiring medical attention, such as worsening shortness of breath, increased edema, weight gain >2 kg in 2 days, dizziness or syncope, chest pain, or further decrease in heart rate, as recommended by the European Society of Cardiology 8
• Emphasize medication adherence strategies and self-monitoring education for effective heart failure management, as recommended by the European Society of Cardiology 4
• Inform patients about the risks of abrupt beta-blocker discontinuation, including rebound hypertension, tachycardia, and myocardial ischemia, and the importance of gradual tapering if discontinuation is necessary, as recommended by the American College of Cardiology 4